GHRP-2 10mg/vial 1 Vial by Bio-Peptide

Usage

1. Gather equipment: Collect the GHRP-2 vial, bacteriostatic water, 1 mL insulin syringes (29–31 G), alcohol swabs, and a sharps container before beginning.
2. Reconstitute correctly: Swab the vial septum, inject 1–2 mL of bacteriostatic water slowly along the vial wall — swirl gently until the lyophilized powder dissolves fully; do not agitate vigorously.
3. Calculate your dose: With 10 mg dissolved in 2 mL, each 0.02 mL (20 µL) on an insulin syringe equals 100 µg — adjust the draw volume to your target research dose (100–300 µg).
4. Select injection timing strategically: Administer GHRP-2 in a fasted state or at least 2 hours after a meal containing carbohydrates or fat; elevated insulin blunts GH pulse amplitude, a key reason GHRP-2 is favoured over GHRP-6 on cuts where frequent small meals are common.
5. Inject subcutaneously: Swab the injection site (abdomen or outer thigh), pinch skin, insert the needle at a 45° angle, aspirate briefly, then deliver the solution slowly and withdraw.
6. Store and document: Refrigerate the reconstituted vial at 2–8 °C, log each dose with timestamp, and discard any unused solution after 28 days or if any visual change occurs.

Warnings

Frequently asked questions

Which GHRP causes more hunger — GHRP-6 or GHRP-2?

GHRP-6 causes significantly more hunger than GHRP-2. Both peptides are ghrelin-receptor agonists, but GHRP-6's binding profile produces a stronger appetite-stimulating signal — potent enough that it has been investigated as a therapeutic appetite promoter in cachexia studies. GHRP-2 activates the same GHS-R1a receptor yet produces roughly 20–30 % less ghrelin-like hunger stimulation, making it the preferred option for users managing strict caloric targets.

Who benefits most from GHRP-6's appetite side effect rather than GHRP-2's?

Hard gainers, off-season athletes pursuing aggressive caloric surpluses, and clinical populations with appetite insufficiency benefit most from GHRP-6's strong hunger signal. Users in a caloric deficit, cutting competitors, or anyone pairing a GHRP with precise macronutrient tracking will find GHRP-2's reduced appetite stimulation far more manageable without sacrificing meaningful GH pulse amplitude.

How does GH output differ between GHRP-6 and GHRP-2 at equivalent doses?

At equivalent dosing (commonly 1 µg/kg body weight), GHRP-2 and GHRP-6 produce comparable peak GH pulse amplitudes as measured in pituitary stimulation studies. The primary difference is not GH output magnitude but rather the side-effect profile: GHRP-2 carries a modestly higher cortisol and prolactin co-stimulation potential at supraphysiological doses, while GHRP-6 carries the stronger appetite liability. GH secretion efficiency is broadly equivalent.

How do I reconstitute and store Bio-Peptide GHRP-2 10mg/vial after opening?

Add 1–2 mL of bacteriostatic water to the lyophilized GHRP-2 powder using a sterile syringe, swirl gently — never shake — and allow to fully dissolve. Once reconstituted, store the vial refrigerated at 2–8 °C and use within 20–28 days. Discard any solution that appears cloudy or particulate. Doses are drawn with an insulin syringe (typically 29–31 G) and administered subcutaneously into the abdomen or outer thigh.

Why is the 10mg/vial format advantageous for a GHRP-2 research cycle?

At 10 mg per vial, Bio-Peptide's GHRP-2 provides the highest per-vial peptide mass in comparable GHRP formats, offering greater dosing flexibility and economy for extended protocols. A standard research dose of 100–300 µg administered two to three times daily yields 33–100 individual doses per vial, substantially reducing reconstitution frequency and minimising degradation risk from repeated vial entry compared to lower-mass alternatives. (2) angle_used

Manufacturer

Bio-Peptide's trajectory as a peptide manufacturer began with a deliberate strategic constraint: the company would not release a batch to market without external laboratory sign-off — a policy that set it apart in a European research-compound sector where self-certified purity claims were commonplace. That constraint shaped the company's entire operational model. Third-party HPLC sequence confirmation and LAL endotoxin certification became embedded production requirements rather than optional quality additions, each certificate tied to a specific batch identifier and available for review. The manufacturing environment operates within cGMP-aligned parameters, covering raw material sourcing, synthesis, lyophilization, and final vial preparation under documented chain-of-custody conditions. Over successive production cycles, this infrastructure-first approach accumulated into a track record that researchers now cite when selecting a GHRP-2 source — reliability and documentation depth rather than marketing claims being the differentiating factor.